Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Does tissue imprinting restrict macrophage plasticity?

(2021) Martin Guilliams et al.   NATURE IMMUNOLOGY

Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

(2020) Simone Ragusa et al.   JOURNAL OF CLINICAL INVESTIGATION

Biology and therapeutic targeting of tumour‐associated macrophages

(2020) Tim Beltraminelli et al.   JOURNAL OF PATHOLOGY

Remodeling of Metastatic Vasculature Reduces Lung Colonization and Sensitizes Overt Metastases to Immunotherapy

(2020) Bo He et al.   Cell Reports

Acquired Resistance to Immune Checkpoint Inhibitors

(2020) Adam J. Schoenfeld et al.   CANCER CELL

IRF4 instructs effector Treg differentiation and immune suppression in human cancer

(2020) Giorgia Alvisi et al.   JOURNAL OF CLINICAL INVESTIGATION

Visualizing and interpreting cancer genomics data via the Xena platform

(2020) Mary J. Goldman et al.   NATURE BIOTECHNOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

(2020) Constance J. Martin et al.   Science Translational Medicine

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

(2020) Shogo Kumagai et al.   NATURE IMMUNOLOGY

Timed Ang2-targeted therapy identifies the Angiopoietin-Tie pathway as key regulator of fatal lymphogenous metastasis

(2020) Nicolas Gengenbacher et al.   Cancer Discovery

Targeting MARCO and IL-37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function

(2020) Linnéa La Fleur et al.   CANCER RESEARCH

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

(2019) Martin Reck et al.   Lancet Respiratory Medicine

Vessel co-option in cancer

(2019) Elizabeth A. Kuczynski et al.   Nature Reviews Clinical Oncology

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response

(2019) Camilla Salvagno et al.   NATURE CELL BIOLOGY

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

(2019) C G Kim et al.   ANNALS OF ONCOLOGY

Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species

(2019) Rapolas Zilionis et al.   IMMUNITY

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vascular regulation of antitumor immunity

(2019) Lance L. Munn et al.   SCIENCE

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

(2019) Scott J Antonia et al.   LANCET ONCOLOGY

Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

(2019) Mariangela Di Tacchio et al.   Cancer Immunology Research

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

(2019) Abhishek S. Kashyap et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development

(2019) Amy Li et al.   Cell Reports

Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer

(2018) Lydia Meder et al.   CANCER RESEARCH

Antiangiogenic therapies in non-small-cell lung cancer

(2018) A. Alshangiti et al.   Current Oncology

Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules

(2018) Bo He et al.   JOURNAL OF PATHOLOGY

RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma

(2018) Julien Faget et al.   Journal of Thoracic Oncology

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

(2018) Marta Román et al.   Molecular Cancer

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

(2018) Xinyi Guo et al.   NATURE MEDICINE

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

(2018) Natalie J. Neubert et al.   Science Translational Medicine

Periostin Limits Tumor Response to VEGFA Inhibition

(2018) Ioanna Keklikoglou et al.   Cell Reports

Lung Interstitial Macrophages: Past, Present, and Future

(2018) Joey Schyns et al.   Journal of Immunology Research

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

(2018) Julie R. Brahmer et al.   Journal for ImmunoTherapy of Cancer

Macrophages of distinct origins contribute to tumor development in the lung

(2018) Pierre-Louis Loyher et al.   JOURNAL OF EXPERIMENTAL MEDICINE

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Snail mediates repression of the Dlk1-Dio3 locus in lung tumor-infiltrating immune cells

(2018) Svenja Groeneveld et al.   Oncotarget

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

(2018) Roberto Ferrara et al.   JAMA Oncology

Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease

(2018) Florence T. H. Wu et al.   BRITISH JOURNAL OF CANCER

Hyperprogressive disease: recognizing a novel pattern to improve patient management

(2018) Stéphane Champiat et al.   Nature Reviews Clinical Oncology

Targeting macrophages: therapeutic approaches in cancer

(2018) Luca Cassetta et al.   NATURE REVIEWS DRUG DISCOVERY

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

(2018) Giuseppe Lo Russo et al.   CLINICAL CANCER RESEARCH

Therapeutic targeting of the angiopoietin–TIE pathway

(2017) Pipsa Saharinen et al.   NATURE REVIEWS DRUG DISCOVERY

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

(2017) Martina Schmittnaegel et al.   Science Translational Medicine

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

(2017) Sean P. Arlauckas et al.   Science Translational Medicine

Neutrophils dominate the immune cell composition in non-small cell lung cancer

(2017) Julia Kargl et al.   Nature Communications

Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer

(2017) Julien Faget et al.   Cell Reports

Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment

(2016) Jin-Sung Park et al.   CANCER CELL

Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages

(2016) Don-Hong Wang et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies

(2016) Daniela F. Quail et al.   CLINICAL CANCER RESEARCH

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity

(2016) Caroline Baer et al.   NATURE CELL BIOLOGY

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

(2016) Jonas Kloepper et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational landscape ofEGFR-,MYC-, andKras-driven genetically engineered mouse models of lung adenocarcinoma

(2016) David G. McFadden et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis

(2016) Sha Zhao et al.   Oncotarget

Immune Checkpoint Modulation for Non-Small Cell Lung Cancer

(2015) J.-C. Soria et al.   CLINICAL CANCER RESEARCH

Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses

(2015) Nikhil S. Joshi et al.   IMMUNITY

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

(2015) Jean-Charles Soria et al.   LANCET ONCOLOGY

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

(2015) F. Skoulidis et al.   Cancer Discovery

DNA mismatch repair deficiency accelerates lung neoplasm development inK-rasLA1/+mice: a brief report

(2015) Charlene M. Downey et al.   Cancer Medicine

Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

(2014) Carola H. Ries et al.   CANCER CELL

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

(2014) Nicolò Rigamonti et al.   Cell Reports

Macrophage Regulation of Tumor Responses to Anticancer Therapies

(2013) Michele De Palma et al.   CANCER CELL

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes

(2012) YOSHIKI SHIGEMATSU et al.   Oncology Letters

Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression

(2011) Michel DuPage et al.   CANCER CELL

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

(2011) Roberta Mazzieri et al.   CANCER CELL

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer

(2010) Katsuhiko Shimizu et al.   Journal of Thoracic Oncology

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

(2009) Michel DuPage et al.   Nature Protocols

Flt-1 Signaling in Macrophages Promotes Glioma Growth In vivo

(2008) M. Kerber et al.   CANCER RESEARCH